JP2021529821A5 - - Google Patents

Info

Publication number
JP2021529821A5
JP2021529821A5 JP2021502435A JP2021502435A JP2021529821A5 JP 2021529821 A5 JP2021529821 A5 JP 2021529821A5 JP 2021502435 A JP2021502435 A JP 2021502435A JP 2021502435 A JP2021502435 A JP 2021502435A JP 2021529821 A5 JP2021529821 A5 JP 2021529821A5
Authority
JP
Japan
Prior art keywords
immunoglobulin
gene therapy
aav
vector
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021502435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529821A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/069280 external-priority patent/WO2020016318A1/en
Publication of JP2021529821A publication Critical patent/JP2021529821A/ja
Publication of JP2021529821A5 publication Critical patent/JP2021529821A5/ja
Priority to JP2024051529A priority Critical patent/JP2024075765A/ja
Priority to JP2026030967A priority patent/JP2026094290A/ja
Pending legal-status Critical Current

Links

JP2021502435A 2018-07-17 2019-07-17 イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法 Pending JP2021529821A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024051529A JP2024075765A (ja) 2018-07-17 2024-03-27 イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法
JP2026030967A JP2026094290A (ja) 2018-07-17 2026-02-27 イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18305971.6 2018-07-17
EP18305971 2018-07-17
US201862768731P 2018-11-16 2018-11-16
US62/768,731 2018-11-16
PCT/EP2019/069280 WO2020016318A1 (en) 2018-07-17 2019-07-17 Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024051529A Division JP2024075765A (ja) 2018-07-17 2024-03-27 イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2021529821A JP2021529821A (ja) 2021-11-04
JP2021529821A5 true JP2021529821A5 (cg-RX-API-DMAC7.html) 2022-05-13

Family

ID=67303476

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021502435A Pending JP2021529821A (ja) 2018-07-17 2019-07-17 イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法
JP2024051529A Pending JP2024075765A (ja) 2018-07-17 2024-03-27 イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法
JP2026030967A Pending JP2026094290A (ja) 2018-07-17 2026-02-27 イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024051529A Pending JP2024075765A (ja) 2018-07-17 2024-03-27 イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法
JP2026030967A Pending JP2026094290A (ja) 2018-07-17 2026-02-27 イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法

Country Status (28)

Country Link
US (3) US20210228738A1 (cg-RX-API-DMAC7.html)
EP (2) EP3768304B1 (cg-RX-API-DMAC7.html)
JP (3) JP2021529821A (cg-RX-API-DMAC7.html)
KR (1) KR20210042308A (cg-RX-API-DMAC7.html)
CN (2) CN112689515A (cg-RX-API-DMAC7.html)
AU (2) AU2019306121B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021000807A8 (cg-RX-API-DMAC7.html)
CA (1) CA3106368A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000112A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021000326A2 (cg-RX-API-DMAC7.html)
DK (1) DK3768304T3 (cg-RX-API-DMAC7.html)
ES (1) ES2935970T3 (cg-RX-API-DMAC7.html)
FI (1) FI3768304T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20221542T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060720T2 (cg-RX-API-DMAC7.html)
IL (1) IL280099A (cg-RX-API-DMAC7.html)
LT (1) LT3768304T (cg-RX-API-DMAC7.html)
MX (1) MX2021000580A (cg-RX-API-DMAC7.html)
PE (1) PE20211859A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550115A1 (cg-RX-API-DMAC7.html)
PL (1) PL3768304T3 (cg-RX-API-DMAC7.html)
RS (1) RS63878B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100306VA (cg-RX-API-DMAC7.html)
SI (1) SI3768304T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300005T1 (cg-RX-API-DMAC7.html)
UA (1) UA130604C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020016318A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100202B (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2985035T3 (es) 2008-09-15 2024-11-04 Uniqure Biopharma B V Mutante de polipéptido de factor IX, sus usos y su procedimiento de producción
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
CA3095179A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US20200165608A1 (en) * 2018-11-23 2020-05-28 Florida State University Research Foundation, Inc. Inhibition of vascular endothelial cell-mediated phagocytic processes for treatment of demyelinating conditions
CN113544278A (zh) * 2019-01-28 2021-10-22 杜克大学 用于逃避体液免疫的组合物和方法
CN114681472B (zh) * 2019-03-13 2023-06-30 中国人民解放军军事科学院军事医学研究院 氨基葡萄糖及其衍生物作为抗病毒药物的应用
CN113727992A (zh) 2019-03-21 2021-11-30 斯特里迪比奥公司 重组腺相关病毒载体
WO2020232044A1 (en) * 2019-05-14 2020-11-19 Biomarin Pharmaceutical Inc. Methods of redosing gene therapy vectors
WO2021067598A1 (en) 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
CN114787180A (zh) 2019-10-17 2022-07-22 斯特里迪比奥公司 用于治疗c型尼曼-匹克病的腺相关病毒载体
MX2022004353A (es) 2019-10-17 2022-07-19 Casete de transferencia de aav.
IL309560B2 (en) * 2019-12-06 2025-05-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
EP4096691A1 (en) 2020-01-28 2022-12-07 Freeline Therapeutics Limited Improved assay for determining neutralising antibody titre to a viral vektor
AU2021218703A1 (en) 2020-02-14 2022-07-28 Ultragenyx Pharmaceutical Inc. Gene therapy for treating CDKL5 deficiency disorder
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
CN111621506B (zh) * 2020-05-09 2021-07-30 华中农业大学 牛支原体分泌蛋白MbovP0145及其应用
GB202007431D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
US20230277633A1 (en) * 2020-06-05 2023-09-07 Shanghai Bao Pharmaceuticals Co., Ltd. Pharmaceutical composition of enzymes and viruses and application thereof
WO2021254479A1 (zh) * 2020-06-18 2021-12-23 上海宝济药业有限公司 一种免疫球蛋白降解酶IdeE的突变体
RU2020122141A (ru) * 2020-07-03 2022-01-04 Максим Петрович Никитин Способ и композиция на основе генотерапевтического агента и антитела, связывающегося с клетками крови
IL299927A (en) * 2020-07-29 2023-03-01 Univ Florida Improved adeno-associated virus-mediated therapies for X-linked retinoschisis
JP2023542614A (ja) 2020-08-19 2023-10-11 サレプタ セラピューティクス, インコーポレイテッド レット症候群の治療のためのアデノ随伴ウイルスベクター
CA3200863A1 (en) * 2020-09-28 2022-03-31 Scout Bio, Inc. Composition and uses thereof
US20230374542A1 (en) 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
CA3206000A1 (en) * 2020-12-23 2022-06-30 Spark Therapeutic, Inc. Methods of enhancing non-viral gene therapy
WO2022192160A1 (en) * 2021-03-08 2022-09-15 The Regents Of The University Of California Lentivirus protection via fc overexpression
WO2022192193A1 (en) * 2021-03-09 2022-09-15 The Board Of Regents Of The University Of Texas System Methods and compositions for mutagenesis screening in mammalian cells
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル, インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドaavビリオン
WO2023280175A1 (en) * 2021-07-06 2023-01-12 National Institute Of Biological Sciences, Beijing Methods for treating complex i deficiencies or cancers by modulating gro3p biosynthesis
JP2024531138A (ja) 2021-08-11 2024-08-29 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 筋ジストロフィーを処置するための組成物および方法
CN118451182A (zh) * 2022-01-28 2024-08-06 北京昌平实验室 环状rna疫苗及其使用方法
EP4349365A1 (en) * 2022-10-07 2024-04-10 Hansa Biopharma AB Co-treatment for gene therapy
CN115558021B (zh) * 2022-12-01 2023-03-17 山东大学 一种转录因子、重组细胞及其在制备肿瘤治疗药物的应用
CN116425873B (zh) * 2023-06-02 2023-09-05 苏州百道医疗科技有限公司 一种抗ck6重组兔单克隆抗体及其应用
CN117126270B (zh) * 2023-10-25 2024-02-13 首都儿科研究所 一种2型人博卡病毒型别特异性抗体及其应用
CN118217443B (zh) * 2024-01-15 2026-04-03 国科温州研究院(温州生物材料与工程研究所) 一种人发角蛋白止血海绵及其制备方法与应用
WO2025155923A1 (en) 2024-01-17 2025-07-24 The Broad Institute, Inc. Aav capsid modifications that enable improved cns-wide gene delivery through interactions with the transferrin receptor
WO2025217163A2 (en) 2024-04-08 2025-10-16 The Broad Institute, Inc. Novel aav capsids binding to human cd59
WO2025217174A1 (en) 2024-04-08 2025-10-16 The Broad Institute, Inc. Aav capsid modifications that enable improved cns-wide gene delivery through interactions with carbonic anhydrase iv
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2026041758A1 (en) * 2024-08-22 2026-02-26 Genethon Modified aav capsid with enhanced transduction efficiency
GB202414654D0 (en) 2024-10-04 2024-11-20 Hansa Biopharma AB Regimen for vector-based therapies
WO2026107393A2 (en) 2024-11-14 2026-05-21 The Broad Institute, Inc. Aav capsid modifications that reduce immunogenicity

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US941A (en) 1838-09-22 Machine for sawing shingles and staves
US5173A (en) 1847-06-26 Machinery for
US5139A (en) 1847-06-05 Cajsfkles
US414A (en) 1837-09-28 Moetise-latch foe
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
WO1995005864A1 (en) 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6579520B2 (en) 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
US6569645B2 (en) 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CN1882693B (zh) 2003-09-15 2012-08-15 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
CN105770871A (zh) 2005-06-09 2016-07-20 汉莎医药有限公司 IdeS蛋白酶(来自于酿脓链球菌)在自身免疫性疾病和移植排斥的治疗中的用途
CA3144493A1 (en) 2006-10-03 2008-04-10 Arbutus Biopharma Corporation Lipid containing formulations
US7649243B2 (en) 2006-11-06 2010-01-19 International Business Machines Corporation Semiconductor structures incorporating multiple crystallographic planes and methods for fabrication thereof
GB0624874D0 (en) 2006-12-13 2007-01-24 Hansa Medical Ab Treatment
CA2705797A1 (en) 2007-11-14 2009-05-22 The Regents Of The University Of California Sterol-modified amphiphilic lipids
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010054384A1 (en) 2008-11-10 2010-05-14 Alnylam Pharmaceuticals, Inc. Lipids and compositions for the delivery of therapeutics
EP3699172A3 (en) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
US10077232B2 (en) 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
GB201103780D0 (en) 2011-03-04 2011-04-20 Hansa Medical Ab Treatment for ige-mediated disease
EP3795581A3 (en) 2011-08-24 2021-06-09 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
GB201115841D0 (en) 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) * 2012-01-26 2012-03-07 Isis Innovation Composition
US9352042B2 (en) 2012-02-24 2016-05-31 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
JP6342886B2 (ja) 2012-04-18 2018-06-13 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia Aavカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
EP2852840B1 (en) 2012-05-23 2019-10-09 F.Hoffmann-La Roche Ag Selection method for therapeutic agents
WO2015006743A1 (en) 2013-07-12 2015-01-15 The Children's Hospital Of Philadelphia Aav vector and assay for anti-aav (adeno-associated virus) neutralizing antibodies
NZ716102A (en) 2013-07-22 2021-12-24 The Children’S Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
CN108697733A (zh) * 2016-01-11 2018-10-23 鲁比厄斯治疗法股份有限公司 与癌症适应症的多模式治疗性细胞体系有关的组合物和方法
AU2017214441B2 (en) 2016-02-04 2021-08-19 Genovis Ab New Streptococcal proteases
WO2018093868A1 (en) 2016-11-16 2018-05-24 University Of Florida Research Foundation, Inc. Immunoglobulin proteases, compositions, and uses thereof
CA3045551A1 (en) 2016-12-16 2018-06-21 Uniqure Ip B.V. Immunoadsorption
EP3589311A1 (en) 2017-03-02 2020-01-08 Genethon Method for removing anti-aav antibodies from a blood-derived composition
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins

Similar Documents

Publication Publication Date Title
FI3768304T3 (fi) Koostumuksia ja menetelmiä geeniterapiavektoreiden transduktion lisäämiseksi tai tehostamiseksi ja immunoglobuliinien poistamiseksi tai vähentämiseksi
US20200231953A1 (en) Compositions and methods for transient delivery of nucleases
Luo et al. Adeno-associated virus-mediated cancer gene therapy: current status
JP2022121630A5 (cg-RX-API-DMAC7.html)
JP2020528734A5 (cg-RX-API-DMAC7.html)
JP2021512649A5 (cg-RX-API-DMAC7.html)
RU2017125234A (ru) Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний
JP2020523321A5 (cg-RX-API-DMAC7.html)
WO2023060269A4 (en) Recombinant adeno-associated viruses for targeted delivery
JP2023537625A5 (cg-RX-API-DMAC7.html)
Xiao et al. Recombinant adeno-associated virus: clinical application and development as a gene-therapy vector
JP2021507687A5 (cg-RX-API-DMAC7.html)
JP2021508241A5 (cg-RX-API-DMAC7.html)
JP2019524090A5 (cg-RX-API-DMAC7.html)
JP2021520811A5 (cg-RX-API-DMAC7.html)
US20240102050A1 (en) Compositions and methods for treatment of neurological disorders
JP2024530023A5 (cg-RX-API-DMAC7.html)
CN117821513A (zh) 治疗退行性眼部疾病的药物组合物及方法
US20230338582A1 (en) Methods of Treating Human X-Linked Retinoschisis Using Gene Therapy
RU2019130004A (ru) Генная терапия при глазных заболеваниях
WO2024220719A1 (en) Modified aav capsids for gene delivery
WO2002087594A1 (en) Non-viral vesicle vector for cardiac specific gene delivery
US20240342314A1 (en) Slc13a5 gene therapy vectors and uses thereof
WO2024015877A9 (en) Novel aav3b capsid variants with enhanced hepatocyte tropism
KR20250114282A (ko) 근육 특이적 조절 카세트